Drug Research

FUJIFILM Announces License Agreement with Novo Nordisk for the Development of iPSC-Derived Cell Therapies

FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), announced that it has entered an agreement to grant global healthcare company Novo Nordisk A/S a non-exclusive right to use FUJIFILM Cellular...

Aurisco to Build Oligonucleotides Manufacturing Facility in China

Aurisco, a pharmaceutical company and contract development and manufacturing organization (CDMO) in China, is cooperating with global life sciences company Cytiva, to build its first Oligo FlexFactory platform for commercial production. The Oligo FlexFactory platform is the first of the...

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and CytomX Therapeutics, Inc., a leader in the field of conditionally activated oncology therapeutics, announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies...

Sartorius, RoosterBio Partner to Advance the Manufacture of Exosomes

Sartorius has extended a strategic collaboration agreement with RoosterBio Inc. to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies. The companies will provide solutions and expertise for a human mesenchymal stem/stromal cell (hMSC) - based...

GHO Capital and The Vistria Group Complete Acquisition of Leading CDMO Alcami Corporation

Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), and The Vistria Group today announced that they have completed the acquisition of Alcami Corporation ("Alcami"), a leading pharmaceutical contract development and manufacturing organization (CDMO), from funds affiliated with Madison...

Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo

Duality Biologics, a clinical-stage biotech company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers and autoimmune diseases, announced a license agreement with Adcendo ApS ("Adcendo"), a biotech company focused on the development of breakthrough...

WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers

WuXi Biologics , a leading global Contract Research, Development, and Manufacturing Organization announced a license agreement with GSK plc under which GSK will have exclusive licenses for up to four bi- & multi-specific TCE antibodies developed using WuXi Biologics' proprietary...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read